CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Fluticasone Furoate and Vilanterol (as trifenatate)

Last Updated: January 15, 2018
Result type: Reports
Project Number: SR0442-000
Product Line: Reimbursement Review

Generic Name: Fluticasone Furoate and Vilanterol (as trifenatate)

Brand Name: Breo Ellipta

Manufacturer: GlaxoSmithKline Inc.

Therapeutic Area: Asthma

Indications: Asthma

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: February 18, 2016

Recommendation Type: List with clinical criteria and/or conditions

Request for Resubmission: Eligible (January 15, 2018)